Deep CRISPR Nuclease Portfolio And Multiple Editing Modalities Accelerates Identification Of Viable Clinical Candidates

By Vasu Kommireddy, Anastasya Birger, Bikash Shakya, Allie Crawley, Matthew Nethery, et. al.

Life Edit has established the most extensive portfolio of compact, mammalian-active nucleases, featuring a wide array of protospacer adjacent motifs (PAMs), thereby enabling comprehensive access to a vast range of human disease mutations. This innovative portfolio includes RNA-guided nucleases, base editors, and reverse transcriptase editors, all of which have been rigorously validated through both in vitro and in vivo models. The technologies are designed for flexible delivery through proprietary platforms, including lipid nanoparticles (LNP), adeno-associated viruses (AAV), and ex vivo methods, ensuring broad applicability across various therapeutic contexts.

By combining cutting-edge genome editing tools with advanced artificial intelligence (AI), structure-guided design, and directed evolution techniques, Life Edit is able to rapidly develop highly specific, potent, and clinically viable genome-editing candidates. This integrated approach accelerates the discovery of novel therapies for a wide spectrum of genetic diseases, providing a robust foundation for advancing precision medicine at an unprecedented pace. Through continuous innovation and a commitment to precision, Life Edit is positioned at the forefront of genome editing, poised to deliver transformative solutions for unmet medical needs.